Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

McKinsey
Boehringer Ingelheim
McKesson
Johnson and Johnson
Moodys
Harvard Business School

Last Updated: September 26, 2022

Details for Patent: 8,906,890


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


Which drugs does patent 8,906,890 protect, and when does it expire?

Patent 8,906,890 protects ANGELIQ and is included in one NDA.

This patent has twenty-two patent family members in seventeen countries.

Summary for Patent: 8,906,890
Title:Very low-dosed solid oral dosage forms for HRT
Abstract: The present invention relates to a very low-dosed dosage form for hormone replacement therapy (HRT). More particularly, the present invention concerns a solid oral dosage form comprising about 0.5 mg estradiol and about 0.25 mg drospirenone, and at least one pharmaceutically acceptable excipient. Despite the very low E2 and DRSP doses it has surprisingly been found that a high proportion of the women suffering from moderate to severe hot flushes actually respond to this treatment. Accordingly, the dosage form of the invention may be used as maintenance HRT or may be used already when HRT is initiated.
Inventor(s): Mletzko; Stephan (Berlin, DE), Schurmann; Rolf (Teltow, DE), Gude; Kerstin (Birkenwerder, DE)
Assignee: Bayer Intellectual Property GmbH (Monheim, DE)
Application Number:13/087,701
Patent Claim Types:
see list of patent claims
Composition; Dosage form; Use;

Drugs Protected by US Patent 8,906,890

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Bayer Hlthcare ANGELIQ drospirenone; estradiol TABLET;ORAL 021355-001 Feb 29, 2012 RX Yes No See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 8,906,890

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
10160072Apr 15, 2010

International Family Members for US Patent 8,906,890

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 080912 See Plans and Pricing
Australia 2011240102 See Plans and Pricing
Brazil 112012026115 See Plans and Pricing
Canada 2795801 See Plans and Pricing
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
McKinsey
Express Scripts
Johnson and Johnson
AstraZeneca
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.